Alopecia Areata: Patches, Causes, and How to Track Regrowth

Alopecia areata affects approximately 2% of the global population at some point in their lifetime, making it one of the most common autoimmune conditions. A large-scale review by Pratt et al. (2017, Nature Reviews Disease Primers) established that alopecia areata involves a loss of immune privilege at the hair follicle, allowing T-cells to attack follicles that they would normally ignore. The result is sudden, smooth, round bald patches that can appear overnight on an otherwise healthy scalp. If you've woken up to find a coin-sized bare spot where hair used to be, you're almost certainly dealing with alopecia areata, not pattern baldness. The two conditions look nothing alike up close, follow completely different trajectories, and require different tracking approaches. The good news is that the majority of patches regrow on their own. The challenge is knowing when they will, whether treatment accelerates it, and how to track what's actually happening.

What is alopecia areata?

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles. Under normal conditions, hair follicles maintain a state of "immune privilege," meaning they are partially shielded from immune surveillance. This is why your immune system doesn't reject your own hair the way it might reject a transplanted organ. In alopecia areata, this immune privilege collapses. CD8+ T-cells swarm around the hair bulb, particularly during the anagen (growth) phase, and release inflammatory cytokines that force the follicle into premature catagen and then telogen. The follicle doesn't die. It's suppressed.

That last distinction is critical. Unlike scarring alopecias, which permanently destroy follicles, alopecia areata leaves the follicle intact. The hair-producing apparatus is still there, sitting dormant beneath the smooth skin of the bald patch. This is why regrowth is possible, often spontaneously, even after months or years of a patch being bare. The follicle is waiting for the immune attack to subside.

Alopecia areata can occur at any age, though onset before age 30 is most common. It affects men and women equally. The classic presentation is one or more smooth, round or oval patches on the scalp, typically 1-5 centimeters in diameter. The skin within the patch isn't scarred, scaly, or inflamed. It's simply bare and smooth. The surrounding hair appears completely normal. This stark contrast between the bare patch and normal adjacent hair is one of the condition's most distinctive features and one of the quickest ways to distinguish it from other types of hair loss.

At the borders of active patches, you may notice exclamation point hairs: short, broken hairs that are narrower at the base than at the tip, giving them a tapered appearance. These hairs are pathognomonic for alopecia areata, meaning they are essentially diagnostic. If your dermatologist sees exclamation point hairs during examination, the diagnosis is highly confident without needing a biopsy.

Types and progression

Alopecia areata exists on a spectrum. Understanding where your case falls helps set realistic expectations for tracking and recovery.

Alopecia areata (patchy). This is the most common form. One to several discrete patches on the scalp, each typically coin-sized. Most people with alopecia areata have this variant and never progress beyond it. Patches may appear one at a time over weeks or months, or several may appear simultaneously. The scalp is the most common location, but patches can also occur in the beard, eyebrows, eyelashes, or body hair.

Alopecia totalis. Complete loss of all scalp hair. This represents a progression from patchy alopecia areata where the immune attack becomes more extensive. It affects approximately 5% of alopecia areata patients. Totalis develops when patches expand and merge until no scalp hair remains, though body hair, eyebrows, and eyelashes may or may not be affected.

Alopecia universalis. Complete loss of all body hair, including scalp, eyebrows, eyelashes, nasal hair, and body hair. This is the most extensive form, affecting roughly 1% of alopecia areata patients. Universalis represents the far end of the severity spectrum and is the most challenging to treat, though even in this form, spontaneous regrowth remains possible.

The course is unpredictable. This is perhaps the most frustrating aspect of alopecia areata. Some people develop a single patch that regrows within months and never returns. Others develop recurrent patches over years. A minority progress from patchy to totalis or universalis. There isn't a reliable way to predict at initial presentation which trajectory a given case will follow. What the research does tell us is that most cases remain patchy. Alkhalifah et al. (2010, Journal of the American Academy of Dermatology) found that the majority of patients with limited patchy alopecia areata experience spontaneous regrowth, with a favorable prognosis inversely related to the extent of hair loss at onset.

Factors associated with a less favorable prognosis include onset before puberty, extensive hair loss at presentation, duration of current episode longer than one year, involvement of the hair margin (ophiasis pattern), concurrent nail changes (pitting, ridging), and a personal or family history of other autoimmune conditions. None of these factors is definitive, but they help clinicians and patients calibrate expectations.

Causes and triggers

The fundamental cause of alopecia areata is autoimmune: CD8+ T-cells lose tolerance for hair follicle antigens and mount an inflammatory attack against the follicle bulb during anagen. But what triggers this loss of tolerance isn't fully understood. Current evidence points to a combination of genetic susceptibility and environmental triggers.

Genetic susceptibility. Alopecia areata has a strong genetic component. Twin studies show a concordance rate of approximately 55% in identical twins (compared to 0% in fraternal twins in the same studies), and first-degree relatives of affected individuals have a 10-20x higher risk than the general population. Genome-wide association studies have identified multiple susceptibility loci, many of which overlap with genes involved in other autoimmune conditions. The HLA region on chromosome 6, which governs immune recognition, is the most consistently implicated.

Environmental triggers. In genetically susceptible individuals, specific events appear to trigger the first episode or subsequent flares. Emotional stress is the most commonly reported trigger in patient surveys, though the evidence for a direct causal link is complicated by recall bias. Physical illness, particularly viral infections, has been associated with onset in some case series. Hormonal changes, including puberty, pregnancy, and menopause, may also trigger episodes. Vaccination has been reported as a temporal trigger in case reports, though population-level studies haven't established a causal relationship.

Association with other autoimmune conditions. People with alopecia areata have a higher-than-average rate of other autoimmune diseases, particularly thyroid disease (Hashimoto's thyroiditis, Graves' disease), vitiligo, type 1 diabetes, and atopic conditions (eczema, asthma, allergic rhinitis). If you have alopecia areata and haven't had your thyroid checked, it's worth doing. Thyroid dysfunction can independently affect hair and may compound the alopecia areata if left unmanaged.

What doesn't cause alopecia areata. It's not caused by your shampoo, your hairstyle, your diet, your hat, or any external product. It's not contagious. It isn't caused by stress alone in someone without genetic susceptibility. Understanding what doesn't cause it helps avoid wasting time and money on interventions that can't address the underlying autoimmune mechanism.

Alopecia areata vs. other types of hair loss

Accurate identification is essential because treatment approaches differ dramatically. Here's how alopecia areata compares to the conditions most commonly confused with it.

Alopecia areata vs. androgenetic alopecia (pattern baldness). Pattern baldness is gradual, taking months to years to become noticeable. It follows predictable geographic patterns: temple recession and crown thinning in men (Norwood scale), central part widening in women (Ludwig scale). The affected hairs undergo miniaturization, becoming progressively thinner, shorter, and lighter with each growth cycle. The scalp in affected areas shows thinning coverage, not bare skin. Alopecia areata is sudden, producing smooth bare patches in days to weeks. The patches are round or oval, the scalp skin is smooth and unscarred, and the surrounding hair is normal thickness. There is no miniaturization gradient. It's all or nothing within the patch boundary.

Alopecia areata vs. telogen effluvium. Telogen effluvium produces diffuse shedding across the entire scalp. There are no discrete bald patches. You notice increased hair fall in the shower, on your pillow, and when brushing, but the scalp doesn't show bare spots. The shedding hairs are full-thickness, normal hairs that entered telogen prematurely. Alopecia areata is focal, not diffuse. If you have specific bare patches with smooth skin and sharp borders, it's not telogen effluvium.

Alopecia areata vs. traction alopecia. Traction alopecia results from sustained tension on hair follicles due to tight hairstyles: braids, ponytails, buns, extensions, or headwear. The hair loss follows the lines of tension, typically at the temples, hairline margins, and part lines. It's gradual and positionally logical. Alopecia areata patches appear in locations that don't correspond to tension lines and develop suddenly rather than progressively.

Alopecia areata vs. tinea capitis (scalp ringworm). Tinea capitis is a fungal infection that can produce bald patches on the scalp, but the patches look different. Fungal patches typically show scaling, redness, and broken-off hair stubs ("black dot" tinea). The borders may be irregular rather than smooth. There may be itching and inflammation. Alopecia areata patches are smooth, non-scaly, non-inflamed, and non-itchy. If a bald patch is scaly or has broken stubs rather than smooth skin, fungal infection should be investigated with a KOH preparation or culture.

The regrowth timeline

The single most reassuring fact about alopecia areata is that the follicles aren't destroyed. They're suppressed. And in the majority of cases with limited patchy involvement, they recover. Alkhalifah et al. (2010, JAAD) reported that 50-80% of patients with limited alopecia areata patches experience spontaneous regrowth within 12 months without any treatment. That's a high rate of natural recovery, and it's important to keep in mind during the anxious early weeks after discovering a patch.

What regrowth looks like. The first sign of recovery is the appearance of fine, white or light-colored vellus hairs within the patch. These aren't the final product. They're the follicle's initial attempt at re-entering anagen after the immune suppression subsides. Over the following weeks, these vellus hairs gradually thicken, lengthen, and begin to regain pigmentation. The progression from white fuzz to pigmented terminal hair typically takes 3-6 months per patch. Full cosmetic recovery, where the regrown hair is indistinguishable from surrounding hair, often takes 6-12 months from the first signs of vellus regrowth.

Regrowth isn't uniform. Different patches on the same person may regrow at different rates. A patch that appeared first might regrow last, while a newer patch might resolve quickly. There's no reliable way to predict which patch will respond first. This is why tracking each patch individually matters: aggregate observations miss the patch-level detail that tells you what's actually happening.

Recurrence is common. Even after complete regrowth, alopecia areata can return. Approximately 50% of patients who achieve regrowth experience at least one additional episode during their lifetime. Recurrence doesn't mean the previous regrowth was wasted or that the condition is getting worse. It means the autoimmune susceptibility remains, and another trigger can reactivate it. Long-term tracking helps you identify personal trigger patterns (seasonal, stress-related, illness-related) that may allow you to anticipate and manage future episodes more effectively.

Treatments and expected response times

Treatment for alopecia areata aims to suppress the local immune response and create conditions for follicle recovery. The approach depends on the extent and duration of hair loss.

Topical corticosteroids. High-potency topical steroids (clobetasol propionate, betamethasone dipropionate) are typically the first-line treatment for limited patchy alopecia areata. They reduce local inflammation and T-cell activity around the follicle. Expect to apply them once or twice daily for 4-8 weeks before seeing initial regrowth signs. Response rates vary, but approximately 50-60% of patients with limited patches show some response. Track each patch individually: note the date you started treatment and photograph the patch weekly so you can detect the first vellus hairs.

Intralesional corticosteroid injections. Dermatologists inject triamcinolone acetonide directly into the bald patches, typically at 4-6 week intervals. This is considered one of the most effective treatments for limited alopecia areata. Regrowth usually begins 4-6 weeks after the first injection. A 2010 review in the British Journal of Dermatology found that intralesional steroids produced regrowth in up to 71% of patients with limited disease. The main limitation is that injections only treat existing patches. They don't prevent new patches from forming elsewhere.

JAK inhibitors. The FDA approved baricitinib (Olumiant) in June 2022 for severe alopecia areata in adults, marking the first systemic treatment specifically approved for the condition. King et al. (2022, New England Journal of Medicine) published the pivotal BRAVE-AA1 trial showing that baricitinib 4 mg daily produced significant hair regrowth at 36 weeks compared to placebo, with approximately 35% of patients achieving 80% or greater scalp coverage. Ritlecitinib was subsequently approved as well. JAK inhibitors work by blocking the Janus kinase pathway that the immune cells use to signal the attack on hair follicles. These medications are reserved for moderate-to-severe cases (50% or more scalp involvement) due to their systemic nature and cost.

Track each patch from first sign to full regrowth

BaldingAI lets you photograph individual alopecia areata patches at consistent angles, measure patch diameter over time, log treatment applications, and track vellus regrowth signs so you and your dermatologist can see exactly what's working.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

Minoxidil as an adjunct. Topical minoxidil (5%) is sometimes used alongside corticosteroids to support and accelerate regrowth once the immune suppression has taken effect. Minoxidil doesn't address the autoimmune mechanism directly, but it can extend the anagen phase and improve the cosmetic quality of regrowing hair. It's typically applied twice daily to affected areas. Don't expect minoxidil alone to resolve alopecia areata patches. Its value is as a complement to immune-modulating treatment.

Other treatments. For extensive alopecia areata that doesn't respond to first-line therapies, dermatologists may consider topical immunotherapy (diphencyprone/DPCP), which works by inducing a controlled allergic reaction that redirects the immune response away from hair follicles. Systemic corticosteroids (oral prednisone) can produce rapid regrowth but aren't suitable for long-term use due to significant side effects. Methotrexate and other immunosuppressants are occasionally used for severe, refractory cases.

How to track alopecia areata patches

Tracking alopecia areata is fundamentally different from tracking pattern baldness. Pattern baldness involves gradual, diffuse changes across zones. Alopecia areata involves discrete, identifiable patches that can be monitored individually. Your tracking system should reflect this.

Photograph each patch individually at a consistent angle and distance. Use close-up shots that clearly show the patch boundaries and any hair within the patch. Include a reference object (a ruler or coin) in at least the first photo for scale. Shoot weekly from the same position. This is easier than it sounds for scalp patches because you can use a phone held at arm's length above your head (for crown patches) or in a mirror (for temporal patches). The key is repeatability. If every photo is taken from a slightly different angle, comparing them becomes unreliable.

Measure patch diameter. Using a soft measuring tape or ruler, measure each patch at its widest point. Record the measurement and date. An expanding patch indicates active disease. A stable patch may be in transition. A shrinking patch, where hair regrowth is closing in from the borders, indicates recovery. Diameter measurements are simple but powerful. They give you an objective number to track alongside your visual impressions.

Note regrowth signs with precision. When you see new growth within a patch, describe what you see. Are the hairs white or pigmented? Fine (vellus) or thick (terminal)? Scattered throughout the patch or concentrated at the borders? These details matter because they indicate where in the regrowth process you are. White vellus hairs are early-stage regrowth. Pigmented terminal hairs growing from the borders inward represent more advanced recovery. Both are positive signs, but they're at different points in the timeline.

Log treatment applications. If you're using topical steroids, minoxidil, or receiving injections, record every application or appointment date. This creates a treatment timeline you can overlay with your patch measurements and photos. Did a patch start shrinking four weeks after beginning topical steroids? Did vellus hairs appear six weeks after the first injection? Without a treatment log, these correlations are lost to imperfect memory.

Track whether patches are expanding, stable, or regrowing. Create a simple status for each patch at each weekly review: active (expanding or newly appeared), stable (unchanged size, no regrowth), or regrowing (vellus hairs visible, borders closing in). This three-category system gives you a quick longitudinal view of each patch's trajectory without requiring elaborate documentation.

Map which patches respond to treatment. Not all patches respond equally to the same treatment. A patch that's been present for three months may respond quickly to intralesional steroids, while an older patch might be slower. By tracking each patch separately, you and your dermatologist can make informed decisions about which patches need more aggressive intervention and which are resolving on their own.

Living with alopecia areata

The psychological impact of alopecia areata is significant and consistently underestimated by people who haven't experienced it. A 2018 systematic review by Liu et al. in the Journal of the American Academy of Dermatology found that patients with alopecia areata had significantly higher rates of anxiety and depression compared to the general population and to patients with many other dermatological conditions. The sudden, visible nature of the hair loss, combined with its unpredictability, creates a specific kind of distress that differs from the gradual acceptance process many people go through with pattern baldness.

It's okay to feel shaken by it. Discovering a bald patch is alarming, especially when you don't know what caused it or whether it will spread. The uncertainty is often worse than the patch itself. Will there be more? Will it grow back? Will people notice? These are normal reactions, not overreactions. Acknowledging the emotional impact is the first step toward managing it productively rather than letting it consume your attention.

Support resources exist and they help. The National Alopecia Areata Foundation (NAAF) provides educational resources, peer support communities, and connections to clinicians who specialize in autoimmune hair loss. Connecting with others who have experienced alopecia areata can significantly reduce the isolation that many patients describe. Cognitive behavioral therapy (CBT) has shown effectiveness in reducing the psychological burden of visible skin and hair conditions. If the anxiety about your patches is affecting your daily functioning, professional support isn't a luxury. It's a practical intervention.

When to consider no treatment. For mild, stable patches that aren't expanding, a "watchful waiting" approach is entirely reasonable. Given that 50-80% of limited patches regrow spontaneously within 12 months, not treating immediately isn't negligence. It's a valid clinical strategy, especially for people who prefer to avoid steroids or who have patches in areas that can be easily concealed. Continue tracking during this period so you can detect expansion early if it occurs, but don't feel obligated to treat a small, stable patch simply because it exists.

Data over panic. Alopecia areata patches look alarming. A smooth bare spot on your scalp feels like a crisis. But the data tells a more measured story. Most patches resolve. The follicles aren't dead. Effective treatments exist for those that don't resolve spontaneously, and new treatments (particularly JAK inhibitors) have expanded the options dramatically in recent years. Your job isn't to panic. It's to document. Weekly photos, diameter measurements, and treatment logs create a record that replaces fear with facts. When you can look at six weeks of data and see that a patch hasn't expanded, or that vellus hairs are appearing at the borders, the emotional weight of the condition becomes far more manageable. That's what tracking does. It converts an unpredictable condition into a series of observable data points that you and your dermatologist can interpret together, calmly and accurately.

Start documenting today. Photograph each patch, note its size, and begin the timeline that will eventually show you whether your patches are stable, regrowing, or need more aggressive intervention. The data won't change your diagnosis, but it will change how you experience it: from uncontrolled uncertainty to informed observation.